BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease
Search BioPortfolio:       
BioNews
Biotechnology, Pharmaceutical, Life Science & Medical News
Track this topic with BioWatch News Alerts: Register | Login
search help

Search Results

Documents 1-25 out of 42 found
  Current Search:  angiomax: 42     

HTML
100%
A Quiet Medicines Co. Raises Questions
The Medicines Co.

MDCO still seems to be playing by its own rules when it comes to making public disclosures about the regulatory status of its experimental hypertension drug Cleviprex.

At an investment conference last Thursday,...

TheStreet.com:  Jun 17 2008 12:14PM
Matching: angiomax
Find similar documents
HTML
100%
A Quiet Medicines Co. Raises Questions
The Medicines Co.

MDCO still seems to be playing by its own rules when it comes to making public disclosures about the regulatory status of its experimental hypertension drug Cleviprex.

At an investment conference last Thursday,...

TheStreet.com:  Jun 17 2008 11:50AM
Matching: angiomax
Find similar documents
HTML
100%
The Medicines Company Hires Glyn R. Parkin as Senior Vice President, International Operations
The Medicines Company (NASDAQ: MDCO) today announced that Glyn R.

Parkin has joined the Company as Senior Vice President, International Operations.

Working with other senior leaders of the Company, Parkin will be responsible for the...

Genetic Engineering News:  Jun 17 2008 4:07PM
Matching: angiomax
Find similar documents
HTML
100%
The Medicines Company Receives FDA Review Letter for Angiomax Supplemental Filing
- (NewsRx.com) -- (NASDAQ: MDCO) announced receipt of a not approvable letter from the U.S.

Food and Drug Administration (FDA) on a supplemental New Drug Application (sNDA) for an additional dosing regimen for Angiomax(R) (bivalirudin) in...

Macro World Investor:  Jun 12 2008 12:08AM
Matching: angiomax
Find similar documents
HTML
100%
The Medicines Company Receives FDA Review Letter for Angiomax Supplemental Filing
- (NewsRx.com) -- (NASDAQ: MDCO) announced receipt of a not approvable letter from the U.S.

Food and Drug Administration (FDA) on a supplemental New Drug Application (sNDA) for an additional dosing regimen for Angiomax(R) (bivalirudin) in...

Calibre Macro World:  Jun 11 2008 10:59PM
Matching: angiomax
Find similar documents
HTML
100%
Sepracor Completes Acquisition of Oryx Pharmaceuticals and Expands Operations in Canada
MARLBOROUGH, Mass.--(HSMN NewsFeed)--Sepracor Inc.

(Nasdaq: SEPR ) announced today that it has completed the acquisition of Oryx Pharmaceuticals Inc., an affiliate of the Arrow Group.

Oryx is a specialty pharmaceutical company that...

Healthcare Sales & Marketing Network:  Jun 6 2008 10:28AM
Matching: angiomax
Find similar documents
HTML
100%
The Medicines Company to Participate in the Seventh Annual Needham & Company, LLC Biotechnology and Medical Te
PARSIPPANY, N.J.--(BUSINESS WIRE)--The Medicines Company (NASDAQ: MDCO) is scheduled to present at The Seventh Annual Needham Biotechnology and Medical Technology Conference on June 12th, at 3:00pm Eastern Time.

A company overview and...

Business Wire:  Jun 5 2008 10:38PM
Matching: angiomax
Find similar documents
HTML
100%
Results Published in New England Journal of Medicine Show Angiomax Improved Net Clinical Outcomes and Resulted
Results Published in New England Journal of Medicine Show Angiomax Improved Net Clinical Outcomes and Resulted in Improved Survival Rates in the Most Severe Heart Attack Patients 2008 JUN 9 - (NewsRx.com) -- The Medicines Company ...
Therapeutics Daily:  Jun 5 2008 10:21PM
Matching: angiomax
Find similar documents
HTML
100%
The Medicines Company to Participate in the Seventh Annual Needham & Company, LLC Biotechnology and Medical Te
PARSIPPANY, N.J.

- (Business Wire) The Medicines Company (NASDAQ: MDCO) is scheduled to present at The Seventh Annual Needham Biotechnology and Medical Technology Conference on June 12th, at 3:00pm Eastern Time.

A company overview and...

Earthtimes.org:  Jun 5 2008 9:14PM
Matching: angiomax
Find similar documents
HTML
100%
::: Sepracor Completes Acquisition of Oryx Pharmaceuticals and Expands Operations in Canada
MARLBOROUGH, Mass.--(BUSINESS WIRE)--Sepracor Inc.

(Nasdaq: SEPR) announced today that it has completed the acquisition of Oryx Pharmaceuticals Inc., an affiliate of the Arrow Group.

Oryx is a specialty pharmaceutical company that...

Biotech Intelligence:  Jun 5 2008 6:45PM
Matching: angiomax
Find similar documents
HTML
100%
Sepracor Completes Acquisition of Oryx Pharmaceuticals and Expands Operations in Canada
MARLBOROUGH, Mass.--(BUSINESS WIRE)--Sepracor Inc.

(Nasdaq: SEPR) announced today that it has completed the acquisition of Oryx Pharmaceuticals Inc., an affiliate of the Arrow Group.

Oryx is a specialty pharmaceutical company that...

Yahoo! Canada:  Jun 3 2008 11:43AM
Matching: angiomax
Find similar documents
HTML
100%
Sepracor Completes Acquisition of Oryx Pharmaceuticals and Expands Operations in Canada
, 7:00 AM EST News source: Business Wire Sepracor Inc.

(Nasdaq: SEPR) announced today that it has completed the acquisition of Oryx Pharmaceuticals Inc., an affiliate of the Arrow Group.

Oryx is a specialty pharmaceutical company that...

Genetic Engineering News:  Jun 3 2008 12:32PM
Matching: angiomax
Find similar documents
HTML
100%
Sepracor Completes Acquisition of Oryx Pharmaceuticals and Expands Operations in Canada
MARLBOROUGH, Mass.

- (Business Wire) Sepracor Inc.

(Nasdaq: SEPR) announced today that it has completed the acquisition of Oryx Pharmaceuticals Inc., an affiliate of the Arrow Group.

Oryx is a specialty pharmaceutical company that...

Earthtimes.org:  Jun 3 2008 11:27AM
Matching: angiomax
Find similar documents
HTML
100%
Sepracor Completes Acquisition of Oryx Pharmaceuticals and Expands Operations in Canada
Company Website: http:www.sepracor.comMARLBOROUGH, Mass.

-- (Business Wire) Sepracor Inc.

(Nasdaq: SEPR) announced today that it has completed the acquisition of Oryx Pharmaceuticals Inc., an affiliate of the Arrow Group.

Oryx is a...

Stockwatch:  Jun 3 2008 11:10AM
Matching: angiomax
Find similar documents
HTML
100%
Sepracor Completes Acquisition of Oryx Pharmaceuticals and Expands Operations in Canada
MARLBOROUGH, Mass.--(BUSINESS WIRE)--Sepracor Inc.

(Nasdaq: SEPR) announced today that it has completed the acquisition of Oryx Pharmaceuticals Inc., an affiliate of the Arrow Group.

Oryx is a specialty pharmaceutical company that...

Business Wire:  Jun 3 2008 11:02AM
Matching: angiomax
Find similar documents
HTML
100%
The Medicines Company Receives FDA Review Letter For Angiomax Supplemental Filing
Current Article Ratings: Patient / Public: Health Professional: Article Opinions: 0 posts (NASDAQ: MDCO) announced receipt of a not approvable letter from the U.S.

Food and Drug Administration (FDA) on a supplemental New Drug Application ...

Medical News Today:  May 30 2008 12:49PM
Matching: angiomax
Find similar documents
HTML
100%
Medicines Company's heart drug not approvable: US FDA
The Medicines Company announced receipt of a not approvable letter from the US Food and Drug Administration (FDA) on a supplemental New Drug Application (sNDA) for an additional dosing regimen for Angiomax (bivalirudin) in the...
PharmaBiz:  May 30 2008 6:14AM
Matching: angiomax
Find similar documents
HTML
100%
The Medicines Company announces receipt of FDA review letter for Angiomax supplemental filing
The Medicines Company (NASDAQ:MDCO), which is focused on advancing the treatment of critical care patients through the delivery of cost-effective medicines to the hospital marketplace, said on 28 May that the company has received a non...
M2:  May 30 2008 2:47AM
Matching: angiomax
Find similar documents
HTML
100%
US FDA rejects new Angiomax ACS use
_ US FDA rejects new Angiomax ACS use.
Marketletter Publications:  May 30 2008 7:13PM
Matching: angiomax
Find similar documents
HTML
100%
The Medicines Company Receives FDA Review Letter for Angiomax Supplemental Filing
- The Medicines Company (NASDAQ: MDCO) announced receipt of a not approvable letter from the U.S.

Food and Drug Administration (FDA) on a supplemental New Drug Application (sNDA) for an additional dosing regimen for Angiomax(R) ...

Pharma Live:  May 29 2008 4:06AM
Matching: angiomax
Find similar documents
HTML
100%
Bivalirudin 'Nonapprovable' for ACUITY Indication
from Heartwire - a professional news service of WebMD Sue Hughes May 28, 2008 The US FDA has issued a 'not approvable' letter to the Medicines Company for an additional dosing regimen for bivalirudin (Angiomax) in the upstream...
Medscape:  May 29 2008 2:55AM
Matching: angiomax
Find similar documents
HTML
100%
Medicines Company receives not approvable letter from FDA for Angiomax
The Medicines Company has received a not approvable letter from the FDA on a supplemental new drug application for an additional dosing regimen for Angiomax in the treatment of acute coronary syndromes initiated in the emergency...
Therapeutics Daily:  May 29 2008 2:28PM
Matching: angiomax
Find similar documents
HTML
100%
Cleviprex(TM) Reduces and Controls Acutely Elevated Blood Pressure in Elderly Patients, According to New Analy
WASHINGTON--(BUSINESS WIRE)--The Medicines Company (NASDAQ: MDCO) today announced that its investigational agent, CleviprexTM (clevidipine butyrate) injectable emulsion was well tolerated in elderly patients and rapidly achieved and...
Yahoo! Canada:  May 29 2008 2:16PM
Matching: angiomax
Find similar documents
HTML
100%
The Medicines Company Receives FDA Review Letter for Angiomax Supplemental Filing
PARSIPPANY, N.J.--(HSMN NewsFeed)--The Medicines Company (NASDAQ: MDCO ) announced receipt of a not approvable letter from the U.S.

Food and Drug Administration (FDA) on a supplemental New Drug Application (sNDA) for an additional dosing...

Healthcare Sales & Marketing Network:  May 28 2008 10:35PM
Matching: angiomax
Find similar documents
HTML
100%
Angiomax Improves Outcomes in Heart Attack Patients
- Angiomax (bivalirudin) significantly improved net clinical adverse events by 24 percent as well as resulted in a reduction in overall mortality by 32 percent and cardiac mortality by 38 percent when compared to heparin plus routine...
Diagnostic & Invasive Cardiology:  May 28 2008 5:35AM
Matching: angiomax
Find similar documents

 

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.  See User Agreement

Send comments and feedback to:
Peter Barfoot Managing Director, BioPortfolio Ltd.
UK Tel: (+44) 1300 321501
USA Voicemail and Fax: (+1) 415 680 2472

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Wessex Barn, Dorchester Road, Frampton, Dorset, DT2 9NB, UK. No.3312883 VAT No. GB 744 6483 10

Copyright © 1997-2008 - BioPortfolio Limited.